[{"id":"b25768d2-e63d-4ef1-89e9-0d4fc5455a84","acronym":"StrateGIST 1","url":"https://clinicaltrials.gov/study/NCT05489237","created_at":"2022-08-05T13:57:06.723Z","updated_at":"2025-02-25T13:13:05.882Z","phase":"Phase 1","brief_title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT05489237 - StrateGIST 1","lead_sponsor":"IDRx, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • velzatinib (GSK6042981)"],"overall_status":"Recruiting","enrollment":" Enrollment 269","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 04/24/2026","primary_completion_date":" 04/24/2026","study_txt":" Completion: 09/13/2026","study_completion_date":" 09/13/2026","last_update_posted":"2025-01-17"}]